Vitamin D status and cognitive performance in community-dwelling adults: A dose-response meta-analysis of observational studies
Frontiers in Neuroendocrinology June 2023, https://doi.org/10.1016/j.yfrne.2023.101080 PDF behind paywall
Janis D. Harse a, Ross J. Marriott a, Kun Zhu b c, Kevin Murray a, Romola S. Bucks d
Low vitamin D status is linked with poorer cognition in adults while findings in relation to high levels are mixed. We performed a systematic review and meta-analyses to examine dose-response associations between 25-hydroxyvitamin D (25OHD) levels and cognitive performance in community-dwelling adults. Thirty-eight observational studies were included in dose-response meta-analyses. Positive, nonlinear associations were identified between baseline 25OHD levels and global cognition in cross-sectional and longitudinal analyses, and for performance in memory and executive function in longitudinal analyses. When restricted to studies involving older adults, the pattern emerged for specific domains in cross-sectional analyses. Poorer performance was associated with low 25OHD levels, while a sharp improvement was associated with levels up to 60-70 nM/L. Further improvement was observed only for longitudinal global cognition. Our findings support the association between low vitamin D and poorer cognition and suggest levels of at least 60 nM/L are associated with better cognition during ageing.
Introduction
Cognitive decline is responsible for significant loss of independence and quality of life among older adults. It is often associated with dementia, a leading worldwide cause of morbidity and mortality (International, 2015). While more prevalent in older age, cognitive decline may commence earlier, and impede higher level functions such as effective participation in the workforce (Anstey et al., 2013). The societal and economic impacts of cognitive decline are increasing with population ageing, and prevention remains a key strategy. Vitamin D deficiency has been linked with poorer cognitive performance and cognitive decline in observational studies (Balion et al., 2012, Etgen et al., 2012, Goodwill and Szoeke, 2017), but results from supplementation trials have been mixed (Bischoff-Ferrari et al., 2020, Goodwill and Szoeke, 2017, Kang et al., 2021). The nature of the relationship between vitamin D and cognitive health appears complex but warrants further investigation.
Vitamin D becomes active in the body as a hormone after undergoing hydroxylation in the liver and kidneys. Levels of circulating vitamin D hormone (VDH) are tightly controlled by parathyroid hormone such that the precursor metabolite, 25-hydroxyvitamin D (25OHD), is most commonly used to measure vitamin D status (Deluca, 2014). While the role of VDH in calcium and bone metabolism is long established, there is ongoing debate concerning optimal 25OHD levels for skeletal health. The US Institute of Medicine suggests that levels of 50 nM/L are adequate for most of the population and there is likely little further skeletal benefit to achieving higher levels (Ross et al., 2011). However, the Endocrine Society recommends targeting higher levels of 75 nM/L (Holick et al., 2011). There is consensus that levels below 25-30 nM/L are deficient and can lead to rickets in children and osteomalacia in adults (Holick et al., 2011).
The mapping of VDH receptors throughout the body has triggered interest in functions beyond skeletal health. VDH is known to modulate general immune, inflammatory, and oxidative pathways, some of which are associated with cellular ageing (Landel, Annweiler, Millet, Morello, & Feron, 2016).
In the brain, VDH receptors are expressed throughout the frontal, temporal and parietal cortices as well as the thalamus, hypothalamus, basal ganglia, hippocampus, amygdala, cerebellum, brainstem nuclei, and ventricular system (Eyles, Smith, Kinobe, Hewison, & McGrath, 2005), areas associated with most aspects of cognition. Biological research supports a neuroprotective role for VDH through numerous mechanisms such as maintaining intraneuronal calcium levels and regulating the release of neurotransmitters such as acetylcholine, dopamine, and serotonin (Garcion, Wion-Barbot, Montero-Menei, Berger, & Wion, 2002). Disruption to cholinergic transmission has been specifically implicated in Alzheimer’s disease (Cédric Annweiler et al., 2010). VDH also stimulates the production of nerve growth factor, neurotrophin 3, and glial cell line-derived neurotrophic growth factor (GDNF), which are required for neuronal growth and differentiation (Cédric Annweiler et al., 2010). In rat models, the upregulation of GDNF by VDH has been correlated with reduced infarct size after cerebral artery ligation (Garcion et al., 2002). In vitro, VDH has been demonstrated to promote macrophage clearance of amyloid beta material, a hallmark of Alzheimer’s disease (AD) (Masoumi et al., 2009). Furthermore, supplementation in animal models has been shown to improve cognitive function, reduce AD biomarkers (Landel et al., 2016) and to protect neurones from excitotoxic insults in a nonlinear, dose-dependent manner (Brewer et al., 2001).
In observational research on adults, low levels of 25OHD are associated with poorer global cognition: A recent meta-analysis that pooled outcomes from 26 observational studies, summarised the risk of poorer cognitive performance as 1.24 (95% CL:1.14, 1.34) times higher for those with low, compared to high, levels of 25OHD (Goodwill & Szoeke, 2017). While the cut-off levels used to categorise 25OHD varied across individual studies, the lowest category fell below 50 nM/L in all but one study (Schneider et al., 2014) while the highest category was above 50 nM/L in all. The relationship between low 25OHD levels and poorer performance is most often noted in relation to global cognition but has also been reported for performance in specific cognitive domains, particularly executive function (Cedric Annweiler et al., 2013). The relationship also appears stronger in cross-sectional than in longitudinal analyses (Goodwill & Szoeke, 2017), suggesting reverse causation may be a factor. Additionally, while the relationship between low levels and poorer cognition is consistent across studies, the relationship at high levels is not. Some suggest cognitive performance improves throughout the range (Ahn & Kang, 2015; C. Annweiler et al., 2016, Chei et al., 2014, Llewellyn et al., 2011, Sakuma et al., 2019), while others suggest there is little improvement above mid-range (Bartali et al., 2014, Breitling et al., 2012, van Schoor et al., 2016). Poorer outcomes have also been reported at high levels (Granic et al., 2015, Maddock et al., 2015).
In most observational studies, circulating 25OHD levels are categorised or treated as a continuous variable, with few attempting to fully characterise the dose-response association. The use of polynomial terms or splines in some studies has suggested nonlinear relationships (Bartali et al., 2014, Breitling et al., 2012; D. M. Lee et al., 2009, Pettersen, 2016, van Schoor et al., 2016), although inflection or threshold levels have varied from 35 nM/L (D. M. Lee et al., 2009) to 120 nM/L (Pettersen, 2016). A nonlinear relationship between vitamin D and cognitive performance is feasible and would help explain the lack of findings in supplementation trials of healthy adults (Bischoff-Ferrari et al., 2020, Kang et al., 2021, Rossom et al., 2012), as those with adequate baseline levels may not derive any benefit.
Over the last decade, dose-response meta-analyses have highlighted nonlinear associations between vitamin D status and other health outcomes such as diabetes (Hou et al., 2021), heart disease and stroke (Sofianopoulou et al., 2021), and mortality (Durup et al., 2012, Sofianopoulou et al., 2021). The relationship between vitamin D status and dementia has also been examined, with the risk of incident dementia reported to decrease as levels of 25OHD increase up to at least 70 nM/L (Jayedi, Rashidy-Pour, & Shab-Bidar, 2019). However, to our knowledge, no meta-analysis has examined the dose-response association between 25OHD levels and cognitive performance. We have conducted a systematic review and dose-response meta-analysis to examine this relationship in community-dwelling adults.
Section snippets
Methods
The protocol was registered at Prospero in July 2019 (CRD42019141263). The review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) (Moher, Liberati, Tetzlaff, & Altman, 2009)….
Results
An initial 1046 citation records were identified, with 57 studies included in the qualitative review and 38 in the dose-response meta-analyses (see Figure 1). Further details concerning the reasons for exclusion at full text review are included in the supplementary material (see Table S2). We emailed the corresponding authors of two studies for further details to enable inclusion in the dose-response meta-analyses. While successful contact was made with one author, this study was ultimately…
Discussion
Our findings support the existence of positive, nonlinear associations between circulating 25OHD levels and cognitive performance, particularly in older adults. This pattern of association was noted for global cognition both cross-sectionally and longitudinally, and for executive function and memory and learning performance on a longitudinal basis. Additionally, when restricted to studies involving older adults (mean age of 65 years plus) in sensitivity analyses, the same pattern emerged for…
Conclusion
In summary, our findings support the existence of positive, nonlinear dose-response associations between circulating 25OHD and cognitive performance, particularly in older adults. The relationship was strongest for global cognition and, with respect to specific domains, was stronger for executive function and memory and learning than for attention and processing speed. Lower baseline levels of 25OHD were associated with poorer performance, while increasing levels up to approximately 60 to 70…
89 References include the recent
- G. Livingston et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission: The Lancet (British edition) (2020)
- L.M.Q. Araujo et al. Functional capacity, renal function and vitamin D in community-dwelling oldest old: International Urology and Nephrology (2019)
- H.A. Bischoff-Ferrari et al. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial: JAMA : the journal of the American Medical Association (2020)
- H. Chen et al. 25-Hydroxyvitamin D Levels and the Risk of Dementia and Alzheimer's Disease: A Dose-Response Meta-Analysis: Frontiers in aging neuroscience (2018)
VitaminDWiki – Overview Alzheimer's-Cognition and Vitamin D contains
- FACT: Cognitive decline is 19X more likely if low vitamin D
- FACT: Dementia is associated with low vitamin D levels.
- FACT: Alzheimer’s Dementia 2.3X more likely in elderly if low vitamin D – Dec 2022
- FACT: Dementia is associated with low vitamin D - many studies
- FACT: Alzheimer's Disease is 4X less likely if high vitamin D
- FACT: Every single risk factor listed for Alzheimer's Disease is also a risk factor for low vitamin D levels
- FACT: Elderly cognition gets worse as the elderly vitamin D levels get even lower (while in senior homes)
- OBSERVATION: Reports of increased vitamin D levels result in improved cognition
- OBSERVATION: Alzheimer’s patients 3X more likely to have a malfunctioning vitamin D receptor gene – 2012
- OBSERVATION: Alzheimer's Disease has been seen to halt when vitamin D was added.
- OBSERVATION: Alzheimer’s is associated with all 7 of the genes which restrict vitamin D
- OBSERVATION: 39 vitamin D and Alz. or Cognition intervention trials as of Sept 2018
- OBSERVATION: 2 Meta-analysis in 2012 agreed that Alzheimer's Disease. associated with low vitamin D
- OBSERVATION: 50X increase in Alzheimer's while decrease in vitamin D
- OBSERVATION: Vitamin D reduces Alzheimer’s disease in 11 ways
- OBSERVATION: Alzheimer’s cognition improved by 4,000 IU of vitamin D
- OBSERVATION: Plaque removed in mice by equiv. of 14,000 IU daily
- OBSERVATION: DDT (which decreases Vit D) increases risk of Alzheimer's by up to 3.8X
- OBSERVATION: 2% of people have 2 copies of the poor gene reference: Alz Org
- OBSERVATION: Genes do not change rapidly enough to account for the huge increase in incidence
- OBSERVATION: End of Alzheimer's videos, transcripts and many studies protocol has been very successful
- It adjusts Vitamin D, B-12, Iron, Omega-3, food, etc, and can now be done at home. $75/month.
- FACT: Vitamin D is extremely low cost and has very very few side effects
- CONCLUSION: Everyone concerned about cognitive decline or Alzheimer's Disease should take vitamin D
- PREDICTION MET: By 2024 Omega-3 and high dose Vitamin D will be found to reverse Alzheimer's in humans
There are 13+ Alzheimer’s meta-analyses in VitaminDWiki
There are 97+ Alzheimer’s studies in VitaminDWiki
Dementia is associated with low vitamin D - many studies 50+ studies
16+ studies in both categories Cognitive and Omega-3
VitaminDWiki – Dementia is associated with low vitamin D - many studies as of June 2023 includes
Vitamin D reduced Dementia in VA by 40% - Dr. Campbell March 2023
50+ Vitamin D pages containing "Dementia" in title
Dementia 2.6 X more likely if very low Vitamin D – March 2023
Dementia again associated with low Vitamin D – 15th study in 10 years – Jan 2023
Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis - 2017
Quality assessment of systematic reviews of vitamin D, cognition and dementia - 2018
Dementia is also associated with Magnesium
Dementia risk increased 1.5X to 1.9X: depends on type of laxative used - Feb 2023